Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
GlaxoSmithKline
Scientific Title
Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors